Iovance Biotherapeutics
IOVA
93 hedge funds and large institutions have $388M invested in Iovance Biotherapeutics in 2016 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 36 increasing their positions, 24 reducing their positions, and 6 closing their positions.
200% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 6
50% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 24
13% more funds holding
Funds holding: 82 → 93 (+11)
9% more capital invested
Capital invested by funds: $357M → $388M (+$31.4M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
82% less call options, than puts
Call options by funds: $1.55M | Put options by funds: $8.43M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$19.8M |
| 2 |
FM
Frazier Management
Seattle,
Washington
|
+$11.1M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$10.3M |
| 4 |
BG
BlackRock Group
London,
United Kingdom
|
+$5.72M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$10.2M |
| 2 |
BC
Broadfin Capital
New York
|
-$4.5M |
| 3 |
Goldman Sachs
New York
|
-$1.78M |
| 4 |
Millennium Management
New York
|
-$1.25M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.02M |
IOVA Hedge Fund Activity: Q3 2016 in Review
93 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2016, worth a combined $388M — up 8.8% from $357M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new IOVA positions and 6 closed out — a net gain of 12 holders — while 36 added to existing stakes and 24 trimmed.
The largest buyer was Victory Capital Management, opening a new position worth an estimated $19.8M. The largest seller was Franklin Resources, cutting an estimated $10.2M.
- 93 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2016, up from 82 in Q2 2016.
- Funds reported $388M of Iovance Biotherapeutics stock for Q3 2016, up 8.8% quarter-over-quarter.
- 18 funds opened new Iovance Biotherapeutics positions in Q3 2016 and 6 closed out, a net change of +12 holders.
- The largest Iovance Biotherapeutics buyer in Q3 2016 was Victory Capital Management, an estimated $19.8M added.
- The largest Iovance Biotherapeutics seller in Q3 2016 was Franklin Resources, an estimated $10.2M sold.
Based on aggregated 13F filings for Q3 2016.